VERU Veru Inc.

NASDAQ
$2.54

Veru Inc. (VERU) is expected to report earnings on December 14, 2026, before the market open. The consensus earnings estimate is a loss of $0.34 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.7% since its last earnings release on August 10, 2026.

Veru Beat Consensus Estimates
Monday, August 10, 2026 · 6:30 AM ET
Earnings Date
4th Quarter, Sep 2026
Dec 14
Monday · 6:30 AM ET
Earnings Whisper
-
vs ($0.34)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.63

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Veru Inc.

Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Charts powered in part by Lightweight Charts™ by TradingView.